^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    JAK inhibitor

    Related drugs:
    3d
    A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets (clinicaltrials.gov)
    P1, N=40, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Completed
    Trial completion
    |
    itraconazole • rifampicin • rovadicitinib (TQ05105)
    6d
    Comparison Between JAK Inhibitors and Traditional Treatment of Rheumatoid Arthritis (clinicaltrials.gov)
    P=N/A, N=72, Not yet recruiting, Assiut University
    New trial
    7d
    Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=39, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Oct 2029 --> Jan 2030 | Trial primary completion date: Oct 2027 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    Xtandi (enzalutamide) • Jakafi (ruxolitinib)
    7d
    A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD) (clinicaltrials.gov)
    P1/2, N=13, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    rovadicitinib (TQ05105)
    12d
    A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease (clinicaltrials.gov)
    P1/2, N=45, Active, not recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Trial completion date: Dec 2024 --> Dec 2026
    Trial completion date
    |
    rovadicitinib (TQ05105)
    13d
    A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy (clinicaltrials.gov)
    P2, N=45, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    13d
    A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray (clinicaltrials.gov)
    P1, N=60, Recruiting, VivaVision Biotech, Inc
    New P1 trial
    17d
    ABX464-103: Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis (clinicaltrials.gov)
    P2, N=355, Completed, Abivax S.A. | Phase classification: P2b --> P2 | N=254 --> 355
    Phase classification • Enrollment change
    |
    mercaptopurine
    21d
    HEMA-MED: A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors (clinicaltrials.gov)
    P1/2, N=26, Recruiting, iOnctura | Initiation date: May 2025 --> Nov 2025
    Trial initiation date
    |
    Jakafi (ruxolitinib) • roginolisib (IOA-244)
    24d
    Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome (clinicaltrials.gov)
    P2, N=56, Recruiting, Icahn School of Medicine at Mount Sinai
    New P2 trial
    26d
    XRPMS: Korean Post-marketing Surveillance for Xeljanz XR (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Pfizer | Trial completion date: Dec 2026 --> Jun 2026 | Trial primary completion date: Dec 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Xeljanz XR (tofacitinib XR)
    1m
    A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) (clinicaltrials.gov)
    P2, N=160, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
    Enrollment open